NecstGen’s Post

The Application of NGS in Hereditary Tumor Analysis Hereditary cancers, including breast, ovarian, and pancreatic cancers, are frequently associated with mutations in specific genes. BRCA1 and BRCA2 are the most prominent genes linked to increased risk for these cancers, but recent advancements in Next-Generation Sequencing (NGS) technology have led to the discovery of additional genes implicated in hereditary tumors. The Role of NGS in Genetic Tumor Analysis NGS technology has significantly enhanced detection efficiency and cost-effectiveness by enabling the simultaneous sequencing of multiple samples and genes. This approach allows for the rapid and economical analysis of a large number of genes, which is crucial for identifying variants in cancer susceptibility genes beyond BRCA1/2. The use of multi-gene panels in research enables the discovery of a broader spectrum of cancer predisposition gene variants, providing patients with more precise genetic risk assessments and personalized treatment strategies. Moreover, NGS facilitates a deeper understanding of cancer drivers, aiding in the development of novel diagnostic tools and therapeutic approaches. A study examined the clinical utility of NGS multi-gene panel testing in patients with a family history of breast, ovarian, or pancreatic cancer, where BRCA1/2 mutations were not detected. The research found that the use of multi-gene panels increased the detection rate of pathogenic mutations by 15% in pancreatic cancer, 8% in breast cancer, and 5% in ovarian cancer cases, indicating that many mutations would have been overlooked without this comprehensive approach. Access the full text: https://lnkd.in/g_yRTi-y HBOC, characterized by BRCA1 and BRCA2 gene mutations, is associated with an increased risk of breast, ovarian, and pancreatic cancers. This review emphasizes that hereditary tumors, such as breast cancer, are syndromes that can lead to the development of various cancers. Understanding cancer susceptibility is essential for updating cancer management protocols, including preventive measures, countermeasures, and treatments, to accurately assess and mitigate the impact of cancer on patients' quality of life. Access the full text: https://lnkd.in/gXAbAgtD NGS technology is pivotal in genetic tumor analysis, enhancing detection efficiency and expanding our comprehension of cancer genetics. Multi-gene panels enable a more comprehensive identification of cancer susceptibility gene variants, offering patients more precise risk assessments and personalized treatment plans. The application of NGS also drives revolutionary progress in cancer research, diagnostics, and therapeutics. #NextGenerationSequencing #HereditaryTumors #BRCA1BRCA2 #MultiGenePanelTesting

📃Scientific paper: Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC) Abstract: Background Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter survival time than other causes. Here we aimed to define castration-dependent and -independent diver genes and molecular pathways in CRPC which are responsible for such lethal metastatic events. Methods By employing digital gene expression (DGE) profiling, the alterations of the epididymal gene expression profile in the mature and bilateral castrated rat were explored. Then we detect and characterize the castration-dependent and -independent genes and pathways with two data set of CPRC-associated gene expression profiles publicly available on the NCBI. Results We identified 1,632 up-regulated and 816 down-regulated genes in rat’s epididymis after bilateral castration. Differential expression analysis of CRPC samples compared with the primary PCa samples was also done. In contrast to castration, we identified 97 up-regulated genes and 128 down-regulated genes that changed in both GEO dataset and DGE profile, and 120 up-regulated genes and 136 down-regulated genes changed only in CRPC, considered as CRPC-specific genes independent of castration. CRPC-specific DEGs were mainly enriched in cell proliferation, while CRPC-castration genes were associated with prostate gland development. NUSAP1 and NCAPG were identified as key... Continued on ES/IODE ➡️ https://etcse.fr/Y8i ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Downregulation and Hypermethylation of GABPB1 Is Associated with Aggressive Thyroid Cancer Features Abstract: SIMPLE SUMMARY: Promoter mutations of the telomerase reverse transcriptase (TERT) gene have been suggested as an oncogenic event in various cancers, including thyroid cancer (TC). GABPB1 is reported to activate TERT gene expression and has been proposed as a cancer therapeutic target. The aim of this study is to explore the fate of TC cells after disruption of GABPB1 and its role in TC. We found that besides the reported oncogenic role of GABPB1 in activating TERT, it also has tumor-suppressive functions in TC. Therefore, targeting GABPB1 for cancer therapy should be cautious since it may counteract its tumor-suppressive functions. ABSTRACT: Promoter mutations of the telomerase reverse transcriptase (TERT) gene occur frequently in thyroid carcinoma (TC), including papillary (PTC) and anaplastic subtypes (ATC). Given that the ETS family transcription factors GABPA and GABPB1 activate the mutant TERT promoter and induce TERT expression for telomerase activation, GABPB1 has been proposed as a cancer therapeutic target to inhibit telomerase. Here, we sought to determine the role of GABPB1 in TC pathogenesis. In TC-derived cells carrying the mutated TERT promoter, GABPB1 knockdown led to diminished TERT expression but significantly increased invasive potentials in vitro and metastatic potential in a xenograft zebrafish model and altered expression of markers for epithelial-to-mesenchymal transition. GABPB1 expression was downregulated in aggressive TCs. Low GABPB1 expr... Continued on ES/IODE ➡️ https://etcse.fr/gx1BI ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations that drive the growth and spread of tumors has opened up new possibilities for the development of more effective and personalized cancer treatments. In this review, we will discuss the different CRISPR-based strategies that have been proposed for cancer therapy, including inactivating genes that drive tumor growth, enhancing the immune response to cancer cells, repairing genetic mutations that cause cancer, and delivering cancer-killing molecules directly to tumor cells. We will also summarize the current state of preclinical studies and clinical trials of CRISPR-based cancer therapy, highlighting the most promising results and the challenges that still need to be overcome. Safety and delivery are also important challenges for CRISPR-based cancer therapy to become a viable clinical option. We will discuss the challenges and limitations that need to be overcome, such as off-target effects, safety, and delivery to the tumor site. Finally, we will provide an overview of the current challenges and opportunities in the field of CRISPR-based cancer therapy and discuss future directions for research and development. The CRISPR system has the potential to change the landscape of cancer research, and this review aims to provide an overview of the current state of the field and the challenges that need to be overcome to realize this potential. https://lnkd.in/eZNr-G-6

Our customers have published a research paper titled “DEPDC1 is a potential therapeutic target in lung adenocarcinoma” on Nano Today. Lung cancer, as a highly malignant neoplasm, leads to elevated morbidity and mortality rates owing to the absence of reliable approaches for prompt diagnosis and intervention. It is crucial to investigate the mechanisms underlying lung cancer development and identify biomarkers to achieve early detection and treatment. In this study, DEP domain containing 1 (DEPDC1), was identified as a hub gene with higher expression in lung adenocarcinoma (LUAD) through weighted gene co-expression network and protein-protein interaction analyses. Patients with high DEPDC1 expression had worse survival rates, and gene set enrichment analysis revealed that DEPDC1 may participate in oncogenic progression via NF-κB-mediated signaling pathways, including the cell cycle and epithelial-mesenchymal transition. In results, DEPDC1 knockdown significantly inhibited cancer cell proliferation and motility. In conclusion, the teams demonstrated that an ionizable lipid nanoparticle delivering DEPDC1 small interfering RNA effectively inhibited tumor growth in vivo, with few systemic adverse effects. Hence, illustrates that DEPDC1 is a potential target for LUAD therapy. siRNA duplexes and Negative control siRNA used in this study were obtained from GenePharma. For more information, please visit: https://lnkd.in/gfmBMFwP

📃Scientific paper: Downregulation and Hypermethylation of GABPB1 Is Associated with Aggressive Thyroid Cancer Features Abstract: SIMPLE SUMMARY: Promoter mutations of the telomerase reverse transcriptase (TERT) gene have been suggested as an oncogenic event in various cancers, including thyroid cancer (TC). GABPB1 is reported to activate TERT gene expression and has been proposed as a cancer therapeutic target. The aim of this study is to explore the fate of TC cells after disruption of GABPB1 and its role in TC. We found that besides the reported oncogenic role of GABPB1 in activating TERT, it also has tumor-suppressive functions in TC. Therefore, targeting GABPB1 for cancer therapy should be cautious since it may counteract its tumor-suppressive functions. ABSTRACT: Promoter mutations of the telomerase reverse transcriptase (TERT) gene occur frequently in thyroid carcinoma (TC), including papillary (PTC) and anaplastic subtypes (ATC). Given that the ETS family transcription factors GABPA and GABPB1 activate the mutant TERT promoter and induce TERT expression for telomerase activation, GABPB1 has been proposed as a cancer therapeutic target to inhibit telomerase. Here, we sought to determine the role of GABPB1 in TC pathogenesis. In TC-derived cells carrying the mutated TERT promoter, GABPB1 knockdown led to diminished TERT expression but significantly increased invasive potentials in vitro and metastatic potential in a xenograft zebrafish model and altered expression of markers for epithelial-to-mesenchymal transition. GABPB1 expression was downregulated in aggressive TCs. Low GABPB1 expr... Continued on ES/IODE ➡️ https://etcse.fr/gx1BI ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Advancing Cancer Therapy with CRISPR-Cas Technology 🧬 I’m excited to share an incredible review article by Mingming Qin, Chunhao Deng, Liewei Wen, Guoqun Luo, and Ya Meng on using CRISPR-Cas for precise gene editing and targeted cancer therapy, published in the Journal of Translational Medicine. Key Highlights: 1. Precision Cancer Therapy: CRISPR-Cas is revolutionizing cancer treatment by enabling precise genetic modifications. This review provides a comprehensive overview of how CRISPR/Cas systems, initially recognized as a bacterial immune response, have become powerful tools for cancer research and therapy. 2. CRISPR Screening: The article dives into the essential components for successful CRISPR screening, including Cas enzymes, guide RNA (gRNA) libraries, and target cells or organs. The authors describe the development of high-throughput gRNA libraries that facilitate personalized treatment strategies for cancer patients. 3. Applications in Cancer Research: CRISPR is being utilized in various applications, including: CAR-T Cell Therapy: Enhancing the precision and efficacy of chimeric antigen receptor (CAR) T-cell treatments for cancer. Drug Target Identification: Discovering new targets for cancer treatment through genome-wide CRISPR-Cas9 knockout screens. Drug Screening and Selection: Employing CRISPR systems to screen for drug resistance genes and to identify potential therapeutic targets in cancer cells and organoids. 4. Future Prospects and Challenges: The review highlights the advantages and potential obstacles of CRISPR in clinical precision medicine. Challenges such as delivery of the CRISPR/Cas system, off-target effects, and limitations in multiple gene-editing are discussed, with insights into ongoing efforts to overcome these barriers. Summary: This review offers a detailed look at the transformative potential of CRISPR-Cas technology in cancer research and therapy, emphasizing its role in advancing precision medicine and genetic therapy. For anyone interested in the future of cancer therapy, this article is a must-read. Full Article: https://lnkd.in/e7MBgjyC #CRISPR #CancerResearch #GeneEditing #PrecisionMedicine #Biotechnology #GeneticTherapy

In a groundbreaking study published in Nature Communications, researchers from the University of Helsinki have developed a remarkable method called ReSisTrace that allows them to trace back pre-existing resistance to cancer treatment using sister cells. By employing genetic barcodes, the researchers labeled cancer cells and allowed them to divide, producing identical sister cells. They then analyzed the gene expression of these sister cells, with half being subjected to chemotherapy or other anticancer treatments while the other half served as a control. By examining the surviving cells, they were able to identify the barcodes associated with resistant cells. Comparing the gene expression of these resistant cells with their pre-treatment sister cells provided insights into the differences that lead to resistance. The researchers discovered that genes related to proteostasis, mRNA surveillance, and DNA repair deficiency played crucial roles in pre-existing resistance. Moreover, they used the gene expression changes to predict small molecules that could reverse the resistant state, making the cancer cells more sensitive to treatment. This innovative approach holds promise for identifying and targeting resistant cell populations across different cancer types and treatment methods, including immunotherapies, ultimately opening the door to sequential cancer therapies that can combat resistance at its earliest stages. https://lnkd.in/eu9-z9DR

Our latest study on Genetic Testing Patterns in Cancer Survivors 🧬 supported by UF Health Cancer Center We analyzed the experiences of over 415,000 cancer survivors using cancer registry-linked survey data 📊 🔍 Key Findings: *17% reported undergoing germline genetic testing *8.5% had tumor genetic testing *Only 8.6% discussed tumor testing with healthcare providers 👩⚕️👨⚕️ Significant disparities emerged: *Higher testing rates among survivors under 65, females, college graduates, and those with private insurance *Ovarian and breast cancer survivors showed 7%-36% higher testing prevalence compared to other cancer types *Recent diagnoses (2015-2017) and advanced-stage cancers were associated with more tumor testing discussions 🔬 Why It Matters?: While genetic testing can provide valuable insights for cancer treatment and prevention, our study reveals that its utilization remains low across most cancer types. This underscores the importance of developing strategies to optimize the integration of genetic testing into oncology practice, ensuring that all eligible patients can benefit from these advances in precision medicine. In collaborations with: 👍 Thomas George Dejana Braithwaite Jiang Bian Ruixuan (Roxanne) Wang Guanming C. Susan Vadaparampil https://lnkd.in/egde-yEg

So inspiring ! The utility of genomic data to help diagnose, treat and follow cancer patients, is once again demonstrated in this study. 🦀🧬 The remaining major question is how now to fasten the accees and the usage of these sequencing technologies for health woldwide!